title: Changes in dialysis treatment modalities during institution of flat rate reimbursement and quality assurance programs.
abstract: Dialysis procedure rates in Germany were changed in 2002 from per-session to weekly flat rate payments, and quality assurance was introduced in 2009 with defined treatment targets for spKt/V, dialysis frequency, treatment time, and hemoglobin. In order to understand trends in treatment parameters before and after the introduction of these changes, we analyzed data from 407 to 618 prevalent patients each year (hemodialysis over 90 days) in 14-21 centers in cross-sections of the Dialysis Outcomes and Practice Patterns Study (phases 1-4, 1998-2011). Descriptive statistics were used to report differences over time in the four quality assurance parameters along with erythropoietin-stimulating agent (ESA) and intravenous iron doses. Time trends were analyzed using linear mixed models adjusted for patient demographics and comorbidities. The proportion of patients with short treatment times (less than 4 h) and low spKt/V (below 1.2) improved throughout the study and was lowest after implementation of quality assurance. Hemoglobin levels have increased since 1998 and remained consistent since 2005, with only 8-10% of patients below 10 g/dl. About 90% of patients were prescribed ESAs, with the dose declining since peaking in 2006. Intravenous iron use was highest in 2011. Hence, trends to improve quality metrics for hemodialysis have been established in Germany even after introduction of flat rate reimbursement. Thus, analysis of facility practice patterns is needed to maintain quality of care in a cost-containment environment.
authors: Gemeinschaftspraxis Karlstrasse, Düsseldorf, Germany. werner@kleophas.de
authors: Werner
authors: W
authors: Kleophas
authors: Angelo
authors: A
authors: Karaboyas
authors: Yun
authors: Y
authors: Li
authors: Juergen
authors: J
authors: Bommer
authors: Helmut
authors: H
authors: Reichel
authors: Andreas
authors: A
authors: Walter
authors: Andrea
authors: A
authors: Icks
authors: Lars C
authors: LC
authors: Rump
authors: Ronald L
authors: RL
authors: Pisoni
authors: Bruce M
authors: BM
authors: Robinson
authors: Friedrich K
authors: FK
authors: Port
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D003363:Cost Control; D004305:Dose-Response Relationship, Drug; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D005858:Germany / Q000453:epidemiology; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood / Q000453:epidemiology* / Q000628:therapy*; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D010818:Practice Patterns, Physicians' / Q000191:economics / Q000639:trends*; D011446:Prospective Studies; D011785:Quality Assurance, Health Care / Q000191:economics / Q000639:trends*; D012051:Reimbursement Mechanisms / Q000191:economics / Q000639:trends*; D006435:Renal Dialysis / Q000191:economics*; D012189:Retrospective Studies; D013997:Time Factors
chemical_list: D006454:Hemoglobins; D004921:Erythropoietin; C100266:erythrogenin; D007501:Iron